Burlington, MA – April 16, 2009 – Terason, the market leading producer of high performance Laptop Ultrasound™ imaging systems today announced that it has reached an agreement with SenoRx, Inc. (NASDAQ) to provide its Terason t3000 ultrasound for the launch of an additional model of the SenoSonix™ System. Like the original SenoSonix, the new model is an integration of SenoRx’s EnCor® breast biopsy system with ultrasound imaging. This new version of the device incorporates a microminiaturization ultrasound technology that combines personal computing power and flexibility designed, developed and marketed by Terason. This versatile ultrasound technology coupled with SenoRx’s proprietary EnCor vacuum – assisted biopsy technology results in an attractive alternative model of the SenoSonix System for customers. The modular design and sophisticated imaging architecture are now available in a reduced footprint with increased portability. The original SenoSonix System received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in October 2007 and CE Mark approval in April 2008.
The Terason t3000 offers best-in-class image quality, ease of use and an integrated information management and communications protocol in one compact system. “Terason’s award winning miniaturized system-on-a-chip architecture, coupled with a Windows®-based software enables SenoRx to integrate EnCor biopsy controls directly into the ultrasound display panel seamlessly,” according to Dr. Alice Chiang, Chief Executive Officer at Terason. “We are happy to be partnering with SenoRx on this new initiative. SenoRx is a leader in their market segment and has been innovative in the promoting enhancement to patient care using ultrasound image guidance,” With the SenoSonix product, surgeons can now use one system to perform biopsy
procedures with greater ease and confidence with ultrasound guidance, eliminating the need for two separate systems.
“The new SenoSonix model is designed to meet the needs of breast surgeons performing breast biopsy procedures utilizing ultrasound in both their offices and in the hospital surgery suite who wish to have the flexibility of moving the ultrasound component between the two locations,” said Lloyd Malchow, SenoRx President and Chief Executive Officer. “The new system may be particularly well suited for markets in Europe and Asia where a significant percentage of biopsy procedures are performed utilizing ultrasound. We will begin introducing this product in the U.S. and in select countries in which we have launched the EnCor breast biopsy system.”
Terason t3000 ultrasound system won the Technology Innovation Award in Portable Ultrasound from Frost and Sullivan last year. Built on an industry respected combination of the Apple PC and Windows Operating System, this ultrasound system provides seamless networking capabilities, EMR and software updates, DICOM, Wireless, Integrated CD/DVD, and USB capability.
About Terason
Terason is the innovator and world’s leader in integrating patented ultrasound microsystem technology with a commercial laptop. This unique system on a chip architecture provides high performance and cost effective ultrasound solution to the point of patient care, and enables other imaging suppliers to embed it into their technology. Terason is entrusted by thousands of clinicians and partners throughout the world for ultrasound diagnosis and interventional guidance. For more information on Terason please visit www.terason.com.
About SenoRx
SenoRx (NASDAQ: SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor® vacuum assisted breast biopsy system and Contura™ MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx’s field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The company’s line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company’s website at www.senorx.com.
Contact
Grace Palma
VP, Marketing
(781) 270 – 4143
